A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for advanced stomach cancer (TASC)

Satoshi Morita, Hideo Baba, Akira Tsuburaya, Hiroya Takiuchi, Takanori Matsui, Yoshihiko Maehara, Junichi Sakamoto

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A randomized phase II clinical trial is being conducted for patients with advanced or recurrent gastric cancer, in order to select the most promising treatment for subsequent evaluation in a large-scale phase III trial. We compare four chemotherapeutic treatments, which include two sequential and two combination regimens using paclitaxel with 5-fluorouracil or S-1, an oral fluorouracil derivative. The primary endpoint is 10-month overall survival rate, while the secondary endpoints are adverse events, time to treatment failure and progression-free survival. A Bayesian method is used to provide a statistical rule for monitoring the trial. Forty patients per treatment regimen (160 in total) were randomized into one of the four regimens using a centralized dynamic method.

Original languageEnglish
Pages (from-to)469-472
Number of pages4
JournalJapanese journal of clinical oncology
Volume37
Issue number6
DOIs
Publication statusPublished - Jun 2007

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for advanced stomach cancer (TASC)'. Together they form a unique fingerprint.

  • Cite this